Investment
Features
FeesSafety
Academy
More
Pluang+

EU approves Dupixent for treating chronic spontaneous urticaria in children aged 2-11 years.

Market News
13 Apr 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 who do not respond well to antihistamines. This approval is based on clinical trial data showing Dupixent significantly reduces hives and itching compared to placebo. Dupixent is now the first targeted treatment for young children with CSU in the EU, expanding its use in pediatric chronic diseases driven by type 2 inflammation. The drug has a known safety profile and is administered via subcutaneous injection under medical supervision or by caregivers at home.

More News (REGN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App